Literature DB >> 25973232

A novel association of adenosine deaminase with paroxysmal atrial fibrillation: a propensity score analysis from a case-control study.

Liang Liu1, Yong-Ming He1, Cui-Fen Hu1, Xin Zhao1, Hai-Feng Xu1, Xiang-Jun Yang1.   

Abstract

BACKGROUND: Prior work has identified age, body mass index, underlying heart disease, and other comorbidities as risk factors for atrial fibrillation. To date, studies have examined single baseline measures of traditional risk factors, and data on biomarker associations are lacking.
OBJECTIVE: We sought to explore novel biochemical measures possibly associated with incident PAF after balancing the traditional risk factors.
METHODS: Men or women aged ≥18 years that were hospitalized between 1(st) Jan. 2010 and 31(st) Dec. 2013 for paroxysmal atrial fibrillation (PAF) and for health checkup (non-PAF) were included. We used propensity score methods to mitigate the influence of the nonrandom selection of PAF and non-PAF patients. Logistic regression was applied for analysis of risk factors for PAF.
RESULTS: A total of 1,802 eligible patients were identified, in whom, 895 patients had at least one exclusion criterion. After excluding these patients, the total analytic cohort numbered 907 patients. Of these, 779 patients were for control group and 128 patients were for PAF group. Propensity score matching was used to obtain a balanced cohort of 124 patients per group. The PAF and non-PAF groups were well matched on demographic and clinical characteristics after propensity matching. Risk factors for PAF on multivariate stepwise logistic regression model included adenosine deaminase (ADA) [odds ratio (OR) =0.9160, P=0.015, 95% confidence interval (CI): 0.8536-0.9829], mitral valvular regurgitation (OR =3.4611, P=0.001, 95% CI: 1.7000-7.0467) and left atrial diameter (OR =1.0913, P=0.001, 95% CI: 1.0387-1.1465). Only the ADA was a protective factor for the occurrence of PAF.
CONCLUSIONS: The ADA seems to be associated with PAF. The current study provides new insights into the prevention and treatment of PAF.

Entities:  

Keywords:  Risk factors; adenosine deaminase (ADA); paroxysmal atrial fibrillation (PAF); propensity score

Year:  2015        PMID: 25973232      PMCID: PMC4419295          DOI: 10.3978/j.issn.2072-1439.2015.04.10

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  34 in total

1.  Effects of adenosine on wavelength of premature atrial complexes in patients without structural heart disease.

Authors:  G Kabell; B J Karas; R Corbisiero; T F Fitzgerald; J R Cook; J B Kirchhoffer
Journal:  Am J Cardiol       Date:  1996-12-15       Impact factor: 2.778

2.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

3.  Postischemic cardiac function recovery in the isolated rat heart: effects of adenosine deaminase and nucleoside transport inhibition.

Authors:  I M Keeling; R P Obermayr; B Schneider; P G Spieckermann
Journal:  Langenbecks Arch Surg       Date:  2000-12       Impact factor: 3.445

4.  The prevalence and predictors of atrial fibrillation in hemodialysis patients.

Authors:  Gürkan Acar; Ahmet Akçay; Ekrem Doğan; Ismet Onder Işik; Abdullah Sökmen; Gülizar Sökmen; Hayriye Sayarlioğlu; Sedat Köroğlu; Alper Buğra Nacar; Cemal Tuncer
Journal:  Turk Kardiyol Dern Ars       Date:  2010-01

5.  Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Alvaro Alonso; Faye L Lopez; Kunihiro Matsushita; Laura R Loehr; Sunil K Agarwal; Lin Y Chen; Elsayed Z Soliman; Brad C Astor; Josef Coresh
Journal:  Circulation       Date:  2011-06-06       Impact factor: 29.690

6.  The interaction of ACP1, ADA1, diabetes and gender in coronary artery disease.

Authors:  Fulvia Gloria-Bottini; Maria Banci; Patrizia Saccucci; Federica Papetti; Anna Neri; Antonio Pietroiusti; Andrea Magrini; Egidio Bottini
Journal:  Am J Med Sci       Date:  2010-08       Impact factor: 2.378

7.  Low serum albumin levels in patients with paroxysmal atrial fibrillation: what does it mean?

Authors:  Yong-Ming He; Xiang-Jun Yang; Jie Hui; Ting-Bo Jiang; Jian-Ping Song; Zhi-Hua Liu; Wen-Ping Jiang
Journal:  Acta Cardiol       Date:  2006-06       Impact factor: 1.718

8.  Adenosine deaminase-related genes: molecular identification, tissue expression pattern and truncated alternative splice isoform in adult zebrafish (Danio rerio).

Authors:  Denis Broock Rosemberg; Eduardo Pacheco Rico; Marcus Rodrigo Guidoti; Renato Dutra Dias; Diogo Onofre Souza; Carla Denise Bonan; Maurício Reis Bogo
Journal:  Life Sci       Date:  2007-10-04       Impact factor: 5.037

9.  Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study.

Authors:  Takeshi Kato; Takeshi Yamashita; Kouichi Sagara; Hiroyuki Iinuma; Long-Tai Fu
Journal:  Circ J       Date:  2004-06       Impact factor: 2.993

10.  Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years.

Authors:  Teresa S M Tsang; Marion E Barnes; Yoko Miyasaka; Stephen S Cha; Kent R Bailey; Grace C Verzosa; James B Seward; Bernard J Gersh
Journal:  Eur Heart J       Date:  2008-07-08       Impact factor: 29.983

View more
  1 in total

1.  Response by Li et al to Letter Regarding Article, "Adenosine-Induced Atrial Fibrillation: Localized Reentrant Drivers in Lateral Right Atria Due to Heterogeneous Expression of Adenosine A1 Receptors and GIRK4 Subunits in the Human Heart".

Authors:  Ning Li; Brian J Hansen; Vadim V Fedorov
Journal:  Circulation       Date:  2016-12-06       Impact factor: 29.690

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.